vasopressin Side Effects
Also known as: Vasostrict
Analysis of 4,135 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
4,135
Death-Related
1,633
39.5% of reports
Hospitalizations
2,378
57.5% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 1,633 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DRUG INEFFECTIVE | 511 |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 354 |
| SEPSIS | 338 |
| OFF LABEL USE | 294 |
| CARDIOGENIC SHOCK | 273 |
| STRESS | 262 |
| VOMITING | 256 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 248 |
| ASCITES | 247 |
| ABDOMINAL DISTENSION | 243 |
| ABDOMINAL PAIN | 241 |
| NAUSEA | 239 |
| HYPONATRAEMIA | 237 |
| APPENDICITIS | 234 |
| APPENDICOLITH | 233 |
| CONDITION AGGRAVATED | 232 |
| CONSTIPATION | 230 |
| DEATH | 217 |
| VENTRICULAR FIBRILLATION | 205 |
| HYPOTENSION | 185 |
Reactions in Hospitalization Reports
Top reactions in 2,378 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| DRUG INEFFECTIVE | 894 |
| HYPOTENSION | 344 |
| OFF LABEL USE | 303 |
| TOXICITY TO VARIOUS AGENTS | 268 |
| CONDITION AGGRAVATED | 253 |
| CARDIOGENIC SHOCK | 237 |
| ACUTE KIDNEY INJURY | 216 |
| INTENTIONAL OVERDOSE | 203 |
| SEPSIS | 201 |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 199 |
| CARDIAC ARREST | 164 |
| VOMITING | 164 |
| LACTIC ACIDOSIS | 145 |
| ABDOMINAL PAIN | 142 |
| SOMNOLENCE | 138 |
| NAUSEA | 136 |
| OVERDOSE | 136 |
| SHOCK | 134 |
| ANAEMIA | 133 |
| STRESS | 131 |
Nearby — Related Medications
What the FAERS Data Reveals About vasopressin Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 4,135 voluntary reports linked to vasopressin and its brand equivalents (Vasostrict), spanning 2004 through 2025. Of those, 1,633 (39.5%) listed death as an outcome and 2,378 (57.5%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 42% were female and 57% male; age distribution skews toward 45-64, with 1,251 reports in that bracket. The single most reported reaction is drug ineffective with 1,262 submissions, followed by off label use and hypotension.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.